Physician profile
Rajesh Kumar Maheshwari
NPI 1740431246
$4,692.60
in general payments reported to CMS, 2019-2025
27 companies · $594 in 2025
The $594 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.64 · 2020: $146 · 2021: $670 · 2022: $1,163 · 2023: $1,009 · 2024: $1,023 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $920.13 | 2020-2025 | Airsupra, Breztri, Fasenra |
| Novo Nordisk INC | $797.14 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $442.17 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $367.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Vbi Vaccine (Delaware) INC. | $351.32 | 2022-2023 | Prehevbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.44 | 2019-2025 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $255.80 | 2022-2025 | Ztlido |
| Amarin Pharma, INC. | $215.50 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $173.96 | 2022 | |
| Pfizer INC. | $135.31 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.73 | 2019-2022 | |
| Redhill Biopharma INC. | $110.04 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Abbvie INC. | $99.97 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $65.75 | 2021 | |
| Aimmune Therapeutics, INC. | $61.15 | 2024-2025 | Zenpep |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.32 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $33.88 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $32.63 | 2021-2022 | |
| Dynavax Technologies Corporation | $29.19 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $22.59 | 2023 | Quviviq |
| Dexcom, INC. | $20.73 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $18.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.20 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $15.79 | 2019 | |
| Astellas Pharma US INC | $14.72 | 2024 | Veozah |
| Eisai INC. | $14.58 | 2021 | |
| Genentech USA, INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Maheshwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.